Overview
Clinical-stage biotechnology company developing innovative small molecule m
Founded
1999
Deals ยท 12mo
3
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Coultreon Biopharma | Apr 2026Participated | $125 MSeries A | |
Third Arc Bio | Feb 2026Participated | $52 MSeries A | |
APS | Dec 2025Participated | $0.86 MOther Equity | |
Frontier Medicines | Feb 2024Participated | $80 MSeries C | |
Coultreon Biopharma | Apr 2026Participated | $125 MSeries A | |
Third Arc Bio | Feb 2026Participated | $52 MSeries A | |
APS | Dec 2025Participated | $0.86 MOther Equity | |
Frontier Medicines | Feb 2024Participated | $80 MSeries C |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 0 | 2 |
| Series C+ | 0 | 1 |
| Other Equity | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Feb '24 | 1 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 1 |
| Jan '26 | 0 |
| Feb '26 | 1 |
| Mar '26 | 0 |
| Apr '26 | 1 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 3 |
| Enterprise Software | 1 |
| Space & Frontier Tech | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 1 |
| $5M-$10M | 0 |
| $10M-$25M | 0 |
| $25M-$50M | 0 |
| $50M-$100M | 2 |
| $100M-$250M | 1 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 3 |
| Europe | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| AbbVie Ventures | 1 |
| abrdn | 1 |
| Andreessen Horowitz | 1 |
| Balyasny Asset Management | 1 |
| BVF Partners | 1 |
| DCVC Bio | 1 |
| Deerfield Management | 1 |
| Droia Ventures | 1 |
| Finchley Healthcare Ventures | 1 |
| Forbion | 1 |
| Freepoint Capital Group | 1 |
| Hillhouse Capital Group | 1 |
| Longwood Fund | 1 |
| Luma Group | 1 |
| Marshall Wace | 1 |
| MPM Capital | 1 |
| Novo Holdings | 1 |
| Occitanie Angels | 1 |
| Omega Funds | 1 |
| RA Capital Management | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 0 | 0% |
| Participating | 4 | 100% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 0 | 0% |
Lead dynamics requires at least one led deal in this range
Team
Chief Business Officer
Director, Customer Insights & Engagement
Chief Commercial Officer
CEO
Director Clinical Pharmacology
Chief Scientific Officer
Chief Medical Officer
Director